PRX-101
/ Phocus Pharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 26, 2026
A study to evaluate the pharmacokinetics, relative bioavailability, safety, tolerability, and pharmacodynamics of oral PRX-101 in healthy participant (Part 1)
(ANZCTR)
- P1 | N=38 | Recruiting | Sponsor: Phocus Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Trial initiation date • Cardiovascular • Ventricular Tachycardia
1 to 1
Of
1
Go to page
1